Drug
Remodulin
Remodulin: highest development phase Post-Market, developed by United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Remodulin NCT02847260 | Post-Market | Pulmonary Arterial Hypertension |
| Remodulin® (treprostinil sodium) Injection NCT00060996 | Phase 3 | Critical Limb Ischemia |
| Remodulin (treprostinil sodium) Injection NCT00067041 | Phase 2/3 | Peripheral Vascular Disease |
Latest
No recent events.
Follow Remodulin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.